Rigel Pharmaceuticals (NASDAQ:RIGL) vs. Roivant Sciences (NASDAQ:ROIV) Critical Review

Roivant Sciences (NASDAQ:ROIV) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Risk & Volatility

Roivant Sciences has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Roivant Sciences and Rigel Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1	2	10	1	2.79
Rigel Pharmaceuticals	1	2	3	0	2.33

Roivant Sciences currently has a consensus price target of $46.64, suggesting a potential upside of 18.43%. Rigel Pharmaceuticals has a consensus price target of $66.75, suggesting a potential upside of 48.88%. Given Rigel Pharmaceuticals’ higher probable upside, analysts clearly believe Rigel Pharmaceuticals is more favorable than Roivant Sciences.

Insider and Institutional Ownership

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Roivant Sciences and Rigel Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26 million	3,443.61	-$299.77 million	($0.63)	-62.51
Rigel Pharmaceuticals	$294.28 million	2.87	$367.02 million	$15.51	2.89

Rigel Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Roivant Sciences and Rigel Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-838.21%	-22.03%	-20.55%
Rigel Pharmaceuticals	106.59%	14.89%	11.99%

Summary

Rigel Pharmaceuticals beats Roivant Sciences on 11 of the 15 factors compared between the two stocks.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes medicines for people with serious hematologic disorders and cancers. Founded in 1996 and based in South San Francisco, California, the company has focused on treatments that target biological pathways involved in disease. Rigel’s marketed products include Tavalisse (fostamatinib), an oral treatment for adults with chronic immune thrombocytopenia who have had an insufficient response to prior treatment, and Rezlidhia (olutasidenib), an oral therapy for certain adults with relapsed or refractory acute myeloid leukemia containing an IDH1 mutation.